Beta-carotene in HIV infection: an extended evaluation

Area of Science:

• Immunology
• Nutritional Science
• Infectious Diseases

Background:

• Previous studies suggested beta-carotene supplementation may boost immune cells, including CD4 cells, in HIV-infected individuals.
• This prompted further investigation into beta-carotene's potential immunomodulatory effects in a larger cohort over an extended period.

Purpose of the Study:

• To prospectively evaluate the efficacy of high-dose beta-carotene supplementation in enhancing immune cell counts in HIV-positive patients.
• To determine if beta-carotene supplementation leads to immuno-enhancement over a three-month period.

Main Methods:

• A prospective, double-blinded study involving HIV-positive patients randomly assigned to receive either 60 mg of beta-carotene three times daily or a placebo.
• All participants received a multivitamin supplement.
• Immune cell subsets, HIV p24 antigen, and clinical parameters were assessed at baseline, 1 month, and 3 months.

Main Results:

• No statistically significant differences in immune cell counts or other measured parameters were observed between the beta-carotene and placebo groups after 1 or 3 months.
• Serum beta-carotene concentrations were higher in the supplemented group, confirming adherence.
• The addition of a multivitamin to both groups may have influenced the results.

Conclusions:

• The study did not replicate previous findings suggesting beta-carotene supplementation increases immune cells in HIV-infected patients.
• The concurrent use of multivitamins might have masked any potential immuno-enhancement from beta-carotene.
• High-dose beta-carotene supplementation is not recommended for HIV-infected patients based on these findings.